Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines

被引:53
作者
Wang, WG [1 ]
Collie-Duguid, E
Cassidy, J
机构
[1] Univ Aberdeen, Inst Med Sci, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland
[2] Univ Glasgow, Dept Med Oncol, Canc Res UK, Glasgow G61 1BD, Lanark, Scotland
关键词
3-hydroxy-3-methylglutaryl coenzyme A; cerivastatin; colorectal cancer; 5-fluorouracil; nuclear factor kappa B;
D O I
10.1016/S0014-5793(02)03575-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cerivastatin is one of the synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors used for the treatment and prevention of hypercholesterolaemia. The observation that patients receiving this drug had a lower incidence at cancer led to our interest in using it as a putative anticancer agent. In this study, we tested the cytotoxicity of cerivastatin on a panel of 5-fluorouracil (5FU) sensitive and resistant cell lines in vitro. Cerivastatin was cytotoxic to both 5FU sensitive and resistant cells. Cerivastatin significantly augmented the cytotoxic effect of 5FU on drug sensitive (6-22-fold) and resistant (229-310-fold) cell lines. Cerivastatin and 5FU acted synergistically. Cerivastatin inhibited nuclear factor kappaB DNA binding activity. The enhancing effect of cerivastatin on 5FU was partially mevalonate pathway independent. Cerivastatin may allow successful 5FU therapy in chemoresistant patients. (C) 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:415 / 420
页数:6
相关论文
共 29 条
[1]  
Agarwal B, 1999, CLIN CANCER RES, V5, P2223
[2]   Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB [J].
Baldwin, AS .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (03) :241-246
[3]   3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer -: A nested case-control study [J].
Blais, L ;
Desgagné, A ;
LeLorier, J .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (15) :2363-2368
[4]   Characterization of the topoisomerase I locus in human colorectal cancer [J].
Boonsong, A ;
Marsh, S ;
Rooney, PH ;
Stevenson, DAJ ;
Cassidy, J ;
McLeod, HL .
CANCER GENETICS AND CYTOGENETICS, 2000, 121 (01) :56-60
[5]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[6]  
Cuthbert JA, 1997, CANCER RES, V57, P3498
[7]  
Danenberg PV, 1999, SEMIN ONCOL, V26, P621
[8]   Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines:: an in vitro study [J].
Denoyelle, C ;
Vasse, M ;
Körner, M ;
Mishal, Z ;
Ganné, F ;
Vannier, JP ;
Soria, J ;
Soria, C .
CARCINOGENESIS, 2001, 22 (08) :1139-1148
[9]  
FARNIER M, 1998, AM J CARDIOL, V82, P31
[10]   Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice [J].
Feleszko, W ;
Zagozdzon, R ;
Golab, J ;
Jakobisiak, M .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (03) :406-411